Centene (NYSE:CNC – Get Free Report) updated its FY 2024 earnings guidance on Thursday. The company provided EPS guidance of 6.800- for the period, compared to the consensus EPS estimate of 6.820. The company issued revenue guidance of $159.0 billion-$161.0 billion, compared to the consensus revenue estimate of $155.6 billion.
Analyst Ratings Changes
A number of brokerages recently issued reports on CNC. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Centene from $82.00 to $87.00 and gave the company a “hold” rating in a report on Friday, August 2nd. JPMorgan Chase & Co. dropped their price objective on shares of Centene from $85.00 to $80.00 and set a “neutral” rating for the company in a report on Wednesday, July 10th. Sanford C. Bernstein dropped their price objective on shares of Centene from $96.00 to $88.00 and set an “outperform” rating for the company in a report on Wednesday. Stephens reaffirmed an “equal weight” rating and issued a $78.00 target price on shares of Centene in a research report on Monday, August 5th. Finally, Jefferies Financial Group cut shares of Centene from a “buy” rating to a “hold” rating and decreased their target price for the company from $83.00 to $69.00 in a research report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Centene has a consensus rating of “Moderate Buy” and a consensus price target of $84.00.
Read Our Latest Stock Analysis on Centene
Centene Stock Up 1.9 %
About Centene
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children’s health insurance program, foster care, medicare-medicaid plans, long-term services and support.
Read More
- Five stocks we like better than Centene
- 3 Healthcare Dividend Stocks to Buy
- Viking Therapeutics Stock: A Pre-Election Bet Worth Considering
- Stock Analyst Ratings and Canadian Analyst Ratings
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- 5 discounted opportunities for dividend growth investors
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with MarketBeat.com's FREE daily email newsletter.